Effects of exogenous ubiquitin in lethal endotoxemia

Matthias Majetschak, Stephen M. Cohn, Jacob A. Nelson, Elizabeth H. Burton, Udo Obertacke, Kenneth G. Proctor

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background. Recent data indicated a potential role for extracellular ubiquitin in hematopoiesis and inflammation. The biological significance and therapeutic potential of these findings in vivo are unknown. Based on its in vitro abilities to inhibit endotoxin-stimulated tumor necrosis factor alpha (TNRα) production, we hypothesized that exogenous ubiquitin has salutary effects on sequelae caused by endotoxin in vivo. Methods. Anesthetized and mechanically ventilated swine were infused with endotoxin for 3 hours. Ubiquitin was administered intravenously either 15 minutes before or 45 minutes after the endotoxin infusion was started. Albumin was administered to a control group. An additional control group received only ubiquitin. Ex vivo endotoxin evoked TNRα production was measured using a whole blood assay. Ubiquitin and TNFα concentrations were determined by enzyme-linked immunosorbent assay. Results. Ubiquitin reduced mortality (P < .05), prevented development of pulmonary failure (P < .05), reduced fluid requirements (P < .05), and diminished erythema and edema formation. Ubiquitin pretreatment was more effective than treatment 45 minutes after an endotoxin infusion was started. In vivo ubiquitin administration alone inhibited ex vivo endotoxin-evoked TNFα secretion, but had no effect on TNRα serum levels after endotoxin infusion. Conclusion. In vivo ubiquitin administration has salutary actions during lethal endotoxemia and inhibits ex vivo whole blood TNFα production upon endotoxin stimulation. The clinical appearance after ubiquitin treatment in endotoxemia indicates the endothelium as another potential target cell population for interactions with ubiquitin. A novel therapeutic approach to a broad variety of diseases, in which endotoxin triggers immune activation, is suggested.

Original languageEnglish (US)
Pages (from-to)536-543
Number of pages8
JournalSurgery
Volume135
Issue number5
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Endotoxemia
Ubiquitin
Endotoxins
Control Groups
Health Services Needs and Demand
Hematopoiesis
Therapeutics
Erythema
Cell Communication
Endothelium
Albumins
Edema
Swine
Tumor Necrosis Factor-alpha
Enzyme-Linked Immunosorbent Assay
Inflammation

ASJC Scopus subject areas

  • Surgery

Cite this

Majetschak, M., Cohn, S. M., Nelson, J. A., Burton, E. H., Obertacke, U., & Proctor, K. G. (2004). Effects of exogenous ubiquitin in lethal endotoxemia. Surgery, 135(5), 536-543. https://doi.org/10.1016/j.surg.2003.09.006

Effects of exogenous ubiquitin in lethal endotoxemia. / Majetschak, Matthias; Cohn, Stephen M.; Nelson, Jacob A.; Burton, Elizabeth H.; Obertacke, Udo; Proctor, Kenneth G.

In: Surgery, Vol. 135, No. 5, 05.2004, p. 536-543.

Research output: Contribution to journalArticle

Majetschak, M, Cohn, SM, Nelson, JA, Burton, EH, Obertacke, U & Proctor, KG 2004, 'Effects of exogenous ubiquitin in lethal endotoxemia', Surgery, vol. 135, no. 5, pp. 536-543. https://doi.org/10.1016/j.surg.2003.09.006
Majetschak M, Cohn SM, Nelson JA, Burton EH, Obertacke U, Proctor KG. Effects of exogenous ubiquitin in lethal endotoxemia. Surgery. 2004 May;135(5):536-543. https://doi.org/10.1016/j.surg.2003.09.006
Majetschak, Matthias ; Cohn, Stephen M. ; Nelson, Jacob A. ; Burton, Elizabeth H. ; Obertacke, Udo ; Proctor, Kenneth G. / Effects of exogenous ubiquitin in lethal endotoxemia. In: Surgery. 2004 ; Vol. 135, No. 5. pp. 536-543.
@article{1ad7c878195042a9bb8d9b1a231a3eb0,
title = "Effects of exogenous ubiquitin in lethal endotoxemia",
abstract = "Background. Recent data indicated a potential role for extracellular ubiquitin in hematopoiesis and inflammation. The biological significance and therapeutic potential of these findings in vivo are unknown. Based on its in vitro abilities to inhibit endotoxin-stimulated tumor necrosis factor alpha (TNRα) production, we hypothesized that exogenous ubiquitin has salutary effects on sequelae caused by endotoxin in vivo. Methods. Anesthetized and mechanically ventilated swine were infused with endotoxin for 3 hours. Ubiquitin was administered intravenously either 15 minutes before or 45 minutes after the endotoxin infusion was started. Albumin was administered to a control group. An additional control group received only ubiquitin. Ex vivo endotoxin evoked TNRα production was measured using a whole blood assay. Ubiquitin and TNFα concentrations were determined by enzyme-linked immunosorbent assay. Results. Ubiquitin reduced mortality (P < .05), prevented development of pulmonary failure (P < .05), reduced fluid requirements (P < .05), and diminished erythema and edema formation. Ubiquitin pretreatment was more effective than treatment 45 minutes after an endotoxin infusion was started. In vivo ubiquitin administration alone inhibited ex vivo endotoxin-evoked TNFα secretion, but had no effect on TNRα serum levels after endotoxin infusion. Conclusion. In vivo ubiquitin administration has salutary actions during lethal endotoxemia and inhibits ex vivo whole blood TNFα production upon endotoxin stimulation. The clinical appearance after ubiquitin treatment in endotoxemia indicates the endothelium as another potential target cell population for interactions with ubiquitin. A novel therapeutic approach to a broad variety of diseases, in which endotoxin triggers immune activation, is suggested.",
author = "Matthias Majetschak and Cohn, {Stephen M.} and Nelson, {Jacob A.} and Burton, {Elizabeth H.} and Udo Obertacke and Proctor, {Kenneth G.}",
year = "2004",
month = "5",
doi = "10.1016/j.surg.2003.09.006",
language = "English (US)",
volume = "135",
pages = "536--543",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of exogenous ubiquitin in lethal endotoxemia

AU - Majetschak, Matthias

AU - Cohn, Stephen M.

AU - Nelson, Jacob A.

AU - Burton, Elizabeth H.

AU - Obertacke, Udo

AU - Proctor, Kenneth G.

PY - 2004/5

Y1 - 2004/5

N2 - Background. Recent data indicated a potential role for extracellular ubiquitin in hematopoiesis and inflammation. The biological significance and therapeutic potential of these findings in vivo are unknown. Based on its in vitro abilities to inhibit endotoxin-stimulated tumor necrosis factor alpha (TNRα) production, we hypothesized that exogenous ubiquitin has salutary effects on sequelae caused by endotoxin in vivo. Methods. Anesthetized and mechanically ventilated swine were infused with endotoxin for 3 hours. Ubiquitin was administered intravenously either 15 minutes before or 45 minutes after the endotoxin infusion was started. Albumin was administered to a control group. An additional control group received only ubiquitin. Ex vivo endotoxin evoked TNRα production was measured using a whole blood assay. Ubiquitin and TNFα concentrations were determined by enzyme-linked immunosorbent assay. Results. Ubiquitin reduced mortality (P < .05), prevented development of pulmonary failure (P < .05), reduced fluid requirements (P < .05), and diminished erythema and edema formation. Ubiquitin pretreatment was more effective than treatment 45 minutes after an endotoxin infusion was started. In vivo ubiquitin administration alone inhibited ex vivo endotoxin-evoked TNFα secretion, but had no effect on TNRα serum levels after endotoxin infusion. Conclusion. In vivo ubiquitin administration has salutary actions during lethal endotoxemia and inhibits ex vivo whole blood TNFα production upon endotoxin stimulation. The clinical appearance after ubiquitin treatment in endotoxemia indicates the endothelium as another potential target cell population for interactions with ubiquitin. A novel therapeutic approach to a broad variety of diseases, in which endotoxin triggers immune activation, is suggested.

AB - Background. Recent data indicated a potential role for extracellular ubiquitin in hematopoiesis and inflammation. The biological significance and therapeutic potential of these findings in vivo are unknown. Based on its in vitro abilities to inhibit endotoxin-stimulated tumor necrosis factor alpha (TNRα) production, we hypothesized that exogenous ubiquitin has salutary effects on sequelae caused by endotoxin in vivo. Methods. Anesthetized and mechanically ventilated swine were infused with endotoxin for 3 hours. Ubiquitin was administered intravenously either 15 minutes before or 45 minutes after the endotoxin infusion was started. Albumin was administered to a control group. An additional control group received only ubiquitin. Ex vivo endotoxin evoked TNRα production was measured using a whole blood assay. Ubiquitin and TNFα concentrations were determined by enzyme-linked immunosorbent assay. Results. Ubiquitin reduced mortality (P < .05), prevented development of pulmonary failure (P < .05), reduced fluid requirements (P < .05), and diminished erythema and edema formation. Ubiquitin pretreatment was more effective than treatment 45 minutes after an endotoxin infusion was started. In vivo ubiquitin administration alone inhibited ex vivo endotoxin-evoked TNFα secretion, but had no effect on TNRα serum levels after endotoxin infusion. Conclusion. In vivo ubiquitin administration has salutary actions during lethal endotoxemia and inhibits ex vivo whole blood TNFα production upon endotoxin stimulation. The clinical appearance after ubiquitin treatment in endotoxemia indicates the endothelium as another potential target cell population for interactions with ubiquitin. A novel therapeutic approach to a broad variety of diseases, in which endotoxin triggers immune activation, is suggested.

UR - http://www.scopus.com/inward/record.url?scp=2342503177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342503177&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2003.09.006

DO - 10.1016/j.surg.2003.09.006

M3 - Article

C2 - 15118591

AN - SCOPUS:2342503177

VL - 135

SP - 536

EP - 543

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 5

ER -